4CPS-298 Efficacy and safety profile of anti-EGFR tyrosine kinase inhibitor therapy in patients with metastatic non-small cell lung cancer

Safety Profile ◽

Kinase Inhibitor ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures

Annals of Oncology ◽

10.1093/annonc/mdx091.023 ◽

2017 ◽

Vol 28 ◽

pp. ii37-ii38

Author(s):

H.J. Koo ◽

M.Y. Kim ◽

C.-M. Choi ◽

J.C. Lee ◽

S. Park

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

T790m Mutation ◽

Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer

Clinical Cancer Research ◽

10.1158/1078-0432.12aacriaslc-b34 ◽

2012 ◽

Vol 18 (3 Supplement) ◽

pp. B34-B34

Author(s):

Rafael Sierra ◽

Anderson Chang ◽

Jason Moffat ◽

Benjamin G. Neel ◽

Ming-Sound Tsao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

10.1158/1538-7445.am2012-1232 ◽

2012 ◽

Author(s):

J Rafael Sierra ◽

Anderson Chang ◽

Jason Moffat ◽

Benjamin G. Neel ◽

Ming-Sound Tsao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Journal of Experimental & Clinical Cancer Research ◽

10.1186/1756-9966-31-80 ◽

2012 ◽

Vol 31 (1) ◽

pp. 80 ◽

Cited By ~ 23

Author(s):

Jian Zhu ◽

Yuyan Wang ◽

Jianchun Duan ◽

Hua Bai ◽

Zhijie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Dna Methylation ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Methylation Status ◽

Small Cell ◽

Small Cell Lung ◽

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

Lung Cancer ◽

10.1016/j.lungcan.2010.10.019 ◽

2011 ◽

Vol 73 (1) ◽

pp. 63-69 ◽

Cited By ~ 31

Author(s):

Ho Yun Lee ◽

Kyung Soo Lee ◽

Myung-Ju Ahn ◽

Hye Sun Hwang ◽

Ju Won Lee ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2009.12.009 ◽

2010 ◽

Vol 69 (1) ◽

pp. 1-12 ◽

Cited By ~ 36

Author(s):

Robert C. Doebele ◽

Ana B. Oton ◽

Nir Peled ◽

D. Ross Camidge ◽

Paul A. Bunn

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Tyrosine Kinase Inhibitor Therapy ◽

New Strategies

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted Oncology ◽

10.1007/s11523-015-0387-4 ◽

2015 ◽

Vol 11 (2) ◽

pp. 167-174 ◽

Cited By ~ 10

Author(s):

J. B. Auliac ◽

C. Fournier ◽

C. Audigier Valette ◽

M. Perol ◽

A. Bizieux ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Tyrosine Kinase Inhibitor Therapy ◽

Egfr Mutated

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

Value in Health ◽

10.1111/j.1524-4733.2008.00415.x ◽

2009 ◽

Vol 12 (1) ◽

pp. 20-27 ◽

Cited By ~ 63

Author(s):

Josh J. Carlson ◽

Louis P. Garrison ◽

Scott D. Ramsey ◽

David L. Veenstra

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutant

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BMC Cancer ◽

10.1186/1471-2407-11-1 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 81

Author(s):

Satoshi Watanabe ◽

Junta Tanaka ◽

Takeshi Ota ◽

Rie Kondo ◽

Hiroshi Tanaka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Clinical Responses